Bayou City Research, Ltd.

Houston, Texas 77024

0 studies enrolling now · 30 studies all time

What they study most

ADHD, ADHD Specifically With Executive Function Impairment, Attention Deficit Disorder With Hyperactivity, Attention Deficit Hyperactivity Disorder, Attention Deficit Hyperactivity Disorder (ADHD), Attention-Deficit Hyperactivity Disorder (ADHD), Autistic Disorder, Behavioral Symptoms, Bipolar Disorder, Crohn's Disease, Major Depressive Disorder, Schizophrenia

Studies at this site

• Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD) — Completed
• A Phase IV Study of the Safety and Efficacy of Aripiprazole in Combination With Lamotrigine in the Long-Term Maintenance Treatment of Patients With Bipolar I Disorder With A Recent Manic or Mixed Episode — Completed
• Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD) — Completed
• A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Classroom Setting — Completed
• A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Naturalistic Setting — Completed
• KP415 Open-Label Safety Study in Children (6-12 Years of Age) With ADHD — Completed
• KP415 Classroom Study in Children (6-12 Years of Age) With ADHD — Completed
• Safety and Efficacy of SPD465 in Adults With ADHD — Completed
• Vyvanse Adolescent Open-Label Safety and Efficacy Extension Study — Completed
• Efficacy and Safety of Lisdexamfetamine Dimesylate (LDX) in Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD) — Completed
• Safety and Efficacy of SPD489 on Executive Function Behaviors in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) — Completed
• Safety and Efficacy Workplace Environment Study of Lisdexamfetamine Dimesylate (LDX) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD) — Completed
• Safety and Efficacy of SPD489 in Adolescent Subjects Aged 13-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD) — Withdrawn before enrolling
• Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder (ADHD) — Completed
• Vortioxetine, 5, 10, and 20 mg, Relapse Prevention Study in Adults With Major Depressive Disorder (MDD) — Completed
• Software Treatment for Actively Reducing Severity of ADHD — Completed
• Crossover Study to Evaluate the Efficacy of AR11 in Pediatric Patients With ADHD in a Laboratory Classroom Setting — Completed
• A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years Old With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting. — Completed
• A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years of Age With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting. — Completed
• Dasotraline Pediatric Extension Study — Completed
• Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder (VLZ-MD-22) — Completed
• The Efficacy and Safety of PRC-063 in Adult ADHD Patients — Completed
• An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of Schizophrenia — Completed
• NWP09 in Children With Attention Deficit Hyperactivity Disorder (ADHD) — Completed
• AR08 for Treatment of ADHD in Children — Completed
• Study of Safety & Tolerability of OPC-34712 as Adjunctive Therapy in Treatment of Adult Patients With Major Depressive Disorder — Completed
• PRC-063 in Adolescent ADHD — Completed
• Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease — Completed
• Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis — Completed
• Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Peri- And Postmenopausal Women With Major Depressive Disorder (DVS 3364) — Completed